China biopharma rebounds as early-stage innovation fuels dealmaking
China’s biopharma sector is entering 2026 with renewed momentum, reinforcing its position as a global engine for early-stage drug innovation. After a prolonged downturn, venture activity in the sector stabilized in 2024 and rebounded throughout 2025, setting the stage for a more resilient, self-funded ecosystem in Q1 2026. While non-Chinese VC participation continues to retreat, rising domestic capital and streamlined clinical infrastructure are supporting a new wave of well-capitalized private companies with globally relevant pipelines.
Year-over-year activity highlights a clear shift toward next-generation modalities. Deal flow is accelerating in precision oncology, antibody-drug conjugates, nucleic-acid therapies, and metabolic disease, even as small-molecule funding contracts. Major outlicensing deals—such as multibillion-dollar RNA-focused partnerships with global pharma companies—underscore China’s growing lead in early-stage asset generation, while selective M&A and IPO successes signal a reopening exit environment. Looking ahead, continued licensing, targeted fundraises, and differentiated science suggest China’s biopharma advantage will likely persist despite rising geopolitical friction.